← Leaderboards
Shan-Lu Liu
University Of Missouri-Columbia
$4,289,781
Attributed
$4,289,781
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2013–21$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$4,289,781 · 6
By mechanism
R01$3,075,783 · 3
R21$821,025 · 2
R56$392,973 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Viral”
- Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
- David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
- Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
- Judith S. Currier · University Of California Los Angeles$185,434,785
- Constance Ann Benson · University Of California, San Diego$165,517,633
Research focus
ViralVirus DiseasesLipidsCellsVirusInfectionInterferonsAntiviral AgentsLeadHiv-1Ebola VirusMediatingMembraneInsightCell MembraneParticleReportingNovel StrategiesHiv InfectionsMurine Leukemia VirusProductionAcquired Immunodeficiency SyndromePathogenesisIntegral Membrane Protein
Grant awards (14)
TIM-mediated Inhibition of HIV Release: Cooperation with SERINC and Antagonism by Nef$331,500
R01 · FY2021 · AI · contact PI
TIM-mediated Inhibition of HIV Release: Cooperation with SERINC and Antagonism by Nef$331,500
R01 · FY2020 · AI · contact PI
TIM-mediated Inhibition of HIV Release: Cooperation with SERINC and Antagonism by Nef$331,500
R01 · FY2019 · AI · contact PI
IFITM-mediated Inhibition of HIV Infection and Viral Countermeasures$350,063
R01 · FY2018 · AI · contact PI
TIM-mediated Inhibition of HIV Release: Cooperation with SERINC and Antagonism by Nef$331,500
R01 · FY2018 · GM · contact PI
IFITM-mediated Inhibition of HIV Infection and Viral Countermeasures$363,045
R01 · FY2017 · AI · contact PI
IFITM-mediated Inhibition of HIV Infection and Viral Countermeasures$340,977
R01 · FY2016 · AI · contact PI
IFITM-mediated Inhibition of HIV Infection and Viral Countermeasures$341,101
R01 · FY2015 · AI · contact PI
Inhibition of Ebolavirus Entry by IFITM2 Protein$174,299
R21 · FY2015 · AI · contact PI
Restriction of Viral Membrane Fusion and Entry by IFITM Proteins$392,973
R56 · FY2014 · AI · contact PI
IFITM-mediated Inhibition of HIV Infection and Viral Countermeasures$354,597
R01 · FY2014 · AI · contact PI
Inhibition of Ebolavirus Entry by IFITM2 Protein$226,101
R21 · FY2014 · AI · contact PI
Novel Cellular Factors Restricting Viral Membrane Fusion$191,875
R21 · FY2014 · AI · contact PI
Novel Cellular Factors Restricting Viral Membrane Fusion$228,750
R21 · FY2013 · AI · contact PI